

1 Seasonal patterns COVID-19 and Flu

2 Like Illnesses comparable

3

4 Martijn J. Hoogeveen¹ and Ellen K. Hoogeveen².

5 1. Department Technical Sciences & Environment, Open University, the Netherlands.

6 2. Department of Internal Medicine, Jeroen Bosch Hospital, Den Bosch, the Netherlands.

7 Corresponding author:

8 Martijn J. Hoogeveen

9 mjhoogeveen@gmail.com

10

11 **Abstract**

12 *Introduction*

13 During the first wave of COVID-19 it was hypothesized that COVID-19 is subject to multi-wave seasonality,
14 such as other respiratory viral infections since time immemorial, including earlier respiratory pandemics. It has
15 already been observed that the COVID-19 community outbreaks appear to have a similar pattern as other
16 influenza like illnesses (ILI). One year into the pandemic, we aimed to test the seasonality hypothesis for
17 COVID-19.

18 *Methods*

19 We gather and calculated the average ILI annual time series based on incidence data from 2016 till 2019 in the
20 Netherlands. And, compared this with two independent COVID-19 time series during 2020/2021 for the
21 Netherlands, plotted on a logarithmic infection scale. We tested our hypothesis by calculating correlation
22 coefficients and, as a sensitivity analysis, by performing univariate regression analysis.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 *Results*

24 The COVID-19 time series strongly and highly significantly correlates with the ILI time series $r(45) = 0.75$ ($p <$
25 0.00001) and $r(45) = 0.798$, $p < 0.00001$). Also the univariate regression analyses that we performed as a
26 sensitivity analysis are all highly significant: respectively $F(1, 43) = 61.45$, $p < 0.0001$, and $F(1, 43) = 81.18$, $p <$
27 0.0001 and the correlations (r^2) are moderate to strong.

28 *Conclusions*

29 Given the strong, and highly significant, correlations between the ILI and COVID-19 time series, we conclude
30 that COVID-19 behaves as seasonal as ILI in a country in the temperate climate zone, such as the Netherlands.
31 Moreover, the COVID-19 peaks are all during flu season, and lows are all in the opposing period as expected.
32 Furthermore, the COVID-19 time series satisfies the two characteristics of earlier pandemics, namely a short first
33 wave at the tail-end of a flu season, and a longer and more intense second wave during the subsequent flu
34 season.

35

36 **1. Introduction**

37 During the first wave of COVID-19 it was hypothesized that COVID-19 is subject to multi-wave seasonality
38 (Kissler et al., 2020; Grech et al., 2020), such as other respiratory viral infections since time immemorial
39 (Moriyama et al., 2020), including earlier respiratory pandemics (Fox et al, 2017). It is observed that the
40 COVID-19 community outbreaks have a similar pattern as other seasonal respiratory viruses (Sajadi et al., 2020;
41 Poole, 2020). Also during the first COVID-19 cycle the data suggested seasonality, comparable to the
42 seasonality of Influenza Like Illnesses (ILI), although the time series were typically too short for definitive
43 conclusions (Hoogeveen et al., 2021). Currently, we are one year into the COVID-19 pandemic, and we can
44 witness in the temperate climate zone in the Northern Hemisphere, a second wave which appears to rise and peak
45 during the boundaries of a typical flu season, as the first cycle before.

46 Currently, it is not yet confirmed that COVID-19 behaves as seasonal as ILI. Therefore, we want to test our
47 hypothesis that COVID-19 is as seasonal as ILI in a country in the temperate climate zone like the Netherlands,
48 and therefore demonstrates similar seasonal patterns. To test our hypothesis, we performed in-depth time series
49 analysis to compare the COVID-19 cycles with the multi-wave seasonality patterns of flu-like illnesses. In
50 addition, we analyzed to what degree the COVID-19 pandemic fulfills the qualitative characteristics of earlier
51 flu-like pandemics and seasonality as mentioned by Fox et al. Particularly, a short first wave at the tail end of a

52 flu season, and a more severe second wave during the following flu season. We further expect peaks to occur
53 within the seasonal boundaries between week 33 (± 2 weeks) and week 11 (± 5 weeks), and the nadir in the
54 opposing period which coincides with allergy season (Hoogeveen, 2020; Hoogeveen et al, 2021).

55 The main objective of this study is to provide a predictive model for subsequent COVID-19 seasonal cycles.

56

57 **2. Methods**

58 **2.1 Data**

59 *ILI incidence*

60 We used data from the Dutch State Institute for Public Health (RIVM) gathered by the Dutch institute for
61 research of the health care (Nivel) about weekly flu-like incidence (WHO code “ILI” - Influenza Like Illnesses).

62 ILI is defined by the WHO as a combination of a measured fever of $\geq 38^{\circ}\text{C}$, and a cough, with an onset within
63 the last 10 days. The Dutch ILI reports are gathered from primary medical care. Primary medical care is the first-
64 line healthcare provided by local, general practitioners to their registered patients as typical in the Netherlands,
65 with its current population of 17.4 million. The reports are confirmed by a positive RIVM laboratory test for ILI.

66 The flu-like incidence metric is a weekly average based on a representative group of 40 primary care units, and
67 calculated using the number of influenza-like reports per primary care unit divided by the number of patients
68 registered at that unit. This is then averaged for all primary care units in the Netherlands, extrapolated to the
69 entire population, and reported as the ‘ILI incidence per 100,000 citizens in the Netherlands’. The datasets run
70 from week 1 of 2016 up to week 52 of 2019 to preclude the COVID-19 measurement and avoid the impact of
71 lockdowns and other COVID-19 restrictions on ILI in the 2020/2021 season. We used these data to calculate the
72 average ILI incidence per week ($n = 52$) as our baseline times series.

73 *COVID-19 incidence*

74 To calculate the COVID-19 incidence, we used the RIVM.nl data set which reports the daily COVID-19
75 incidence per municipality. The incidence per municipality is based on positive COVID-19 tests that are reported
76 via the local municipality health services (Gemeentelijke Gezondheidsdienst; GGD), that are under control of the
77 RIVM. We aggregated the crude number into a weekly COVID-19 incidence for the Netherlands per 100,000
78 citizens, to create a metric on the same scale as the standard ILI metric. We calculated the values from week 13,
79 2020, the peak of the short first COVID-19 cycle in the Netherlands, till week 5, 2021 ($n = 45$). We assume that

80 the cycles themselves are sufficiently representative for time series analysis, even though the COVID-19
81 incidence during the first cycle is most likely underestimated compared to incidence during the second cycle, due
82 to test bias. With test bias, we mean that both the method of testing and the test capacity, altered during the
83 development of the COVID-19 pandemic.

84 Therefore, as a sensitivity analysis, we used a second dataset from RIVM, which is based on data of the Dutch
85 national intensive care evaluation (NICE) foundation. Based on hospital admissions, the RIVM estimated the
86 COVID-19 incidence in the Netherlands, assuming a delay of at least 7 days between the COVID-19 infection
87 and hospital admission. This dataset provides the average COVID-19 incidence per day with a 95% confidence
88 interval (95% CI). Again, we calculated the average weekly COVID-19 incidence for the Netherlands per
89 100,000 citizens, to create a metric on the same scale as the standard ILI metric.

90

91 **2.2 Statistical analysis**

92 Variables are presented with their means (M) and standard deviations (SD).

93 We calculated correlation coefficients to test the hypotheses and to assess the strength and direction of
94 relationships.

95 Linear regression (F-test) on the ILI and COVID-19 time series are performed as a sensitivity analysis and used
96 *descriptively* to determine the strength of the relationship between the COVID-19 and ILI time series. More in
97 detail to determine the equation using estimates and intercept values, probability, significance level, F-value, and
98 the Multiple R squared correlation to understand the predictive power of the respective relation. Standard
99 deviations and errors, and degrees of freedom (DF) were used as input for calculating the 95% probability
100 interval.

101 We have reported in the text the outcome of statistical tests in APA style, adapted to journal requirements. For
102 all time series we have used the \log_{10} function to transform the data, to compensate for skewness or non-linear
103 patterns, as it makes the relationships between variables appear linear, before calculation correlation coefficients
104 and applying linear regression. The outcome of \log_{10} were multiplied with factor 2 to create an intuitive scale
105 from 0 to 10 for ILI and CLI, which is quite similar to the [1, 12] logarithmic Richter scale for earthquakes
106 (Boore, 1989). The logarithmic scale we elaborated is rational, plots exponential characteristics on a linear

107 infections scale (Steffen, 2018). We added descriptive labels to each scale as an aid for qualitative interpretation
108 and comparison.

109 Correlations are calculated manually in Excel, and for linear regression Graphpad 2021 is used.

110

111 **3. Results**

112 **3.1 Data analysis**

113 The means and standard deviations of the dataset are summarized in Table 1.

114 Figure 1 shows a short first COVID-19 wave at the tail end of the 2019/2020 flu season, and a more severe
115 second wave during the 2020/2021 flu season in terms of total incidence. The peaks are all within the seasonal
116 boundaries between week 33 (± 2 weeks) and week 11 (± 5 weeks), and the nadirs in the opposing period. The
117 hospitalizations based estimates for COVID-19 incidence provide likely a more realistic picture of especially, the
118 first wave, given test bias. However, on a logarithmic scale, the first COVID-19 wave appears more visually
119 comparable in both time series.

120 On our logarithmic infection scale (Fig. 2), the estimated COVID-19 incidence tops around 6 (severe epidemic
121 level) and the nadir bottoms out around 3 (sever outbreak level). Interestingly, on this scale it becomes visible
122 that COVID-19 incidence starts to rise slightly earlier than what's usual for ILI (week 33 ± 2 weeks).

123

124 **3.2 Statistical outcomes**

125 The COVID-19 time series strongly and highly significantly correlates with the ILI time series $r(45) = 0.75$ ($p <$
126 0.00001). The alternative, hospitalizations-based, COVID-19 time series, which provides estimates that seems to
127 control for test bias, correlates even somewhat stronger, ($r(45) = 0.798$, $p < 0.00001$), and as significantly. The
128 correlations with the 95% CI lower and higher boundaries of the estimated COVID-19 incidence time series are
129 very close, respectively $r(45) = 0.788$, $p < 0.00001$ and $r(45) = 0.803$, $p < 0.00001$. Therefore, we conclude that
130 the COVID-19 time series have a similar wave pattern to the ILI time series, which have long been established
131 as being seasonal. Furthermore, the COVID-19 peaks, similar to ILI peaks, all happen during flu season, i.e.,
132 between week 33 (± 2 weeks) and week 11 (± 5 weeks). And, the COVID-19 nadirs, similar to ILI nadirs,
133 happen all in the opposing allergy season.

134 As a second sensitivity analysis, we performed univariate regression analyses between both COVID-19 time
135 series, and the average ILI time series. The outcomes were again highly significant: respectively $F(1, 43) =$
136 $61.45, p < 0.0001$, and $F(1, 43) = 81.18, p < 0.0001$ and the correlations (r^2) are moderate to strong (see Table 3).

137

138 **4. Discussion**

139 Given the strong, and highly significant, correlations between the ILI and COVID-19 time series, we conclude
140 that COVID-19 behaves as seasonal as ILI in a country in the temperate climate zone, such as the Netherlands.
141 Moreover, the COVID-19 peaks are all during flu season, and lows are all in the opposing period as expected.
142 Furthermore, the COVID-19 time series satisfies the two characteristics of earlier pandemics (Fox et al, 2017),
143 namely a short first wave at the tail-end of a flu season, and a longer and more intense second wave during the
144 subsequent flu season. This implies that it makes the subsequent endings and starts of each following wave
145 predictable. If the history of pandemics (Fox et al, 2017) is followed, the third COVID-19 would be less severe
146 than the second one, even without a vaccine.

147 Interestingly, all over Europe the COVID-19 cycles were all more or less in sync with the Dutch COVID-19
148 cycle (Reuters, 2021), and thus ILI seasonality, independent of the start of the first cycle, the severity of
149 lockdown measures taken, and given that herd immunity is not yet reached. The seasonality pattern of COVID-
150 19 appears to be influenced though not caused by social distancing and lockdown measures as these measures
151 were mainly anti-cyclical and following the trend. They were increasingly applied to flatten the curve after
152 COVID-19 incidence increases, gradually lifted after the sharper than expected COVID-19 downcycles in Spring
153 and Summer, and only re-applied after the second wave seriously kicked in, during Autumn and Winter. It is
154 beyond our research to quantify the considerable impact of lockdown and social distancing measures, although it
155 might explain that COVID-19 incidence on the logarithmic scale (see Fig. 2) starts to rise slightly earlier than
156 what's usual for ILI (week 33 ± 2 weeks) as social distancing and lockdown measures were increasingly relaxed
157 and ignored in this period.

158 What environmental factors have caused COVID-19 seasonality? We have analyzed before that the likely
159 inhibiting factor causing ILI seasonality, before or during COVID-19, are seasonal allergens (i.e, pollens) and
160 seasonal allergies (Hoogeveen, 2020, Hoogeveen et al, 2021), given that meteorological factors alone are not
161 sufficient to explain the seasonality of ILI (Tamerius et al., 2011) or COVID-19 (Kerr et al, 2020). The inverse

162 seasonality of seasonal allergens and ILI including COVID-19 is independently confirmed by a recent Chicago
163 study that covered not only for pollens but also mold spores (Shah et al, 2021).

164 At the other hand, we identified solar radiation (UV) as an ILI/COVID-19 co-inhibitor, and it is well-established
165 that dry, warm and sunny weather stimulate the maturation and dispersion of pollens.

166 Although the allergenic role of pollen is widely known (Klemens et al, 2007; Rosenwasser, 2011; Howarth,
167 2000), its role in immuno-activation (Brandelius et al, 2020) is highlighted only recently. Owing to extensive
168 COVID-19 research, pathophysiological explanations have been established upon the observation that allergic
169 diseases are associated with lower rates of COVID-19 hospitalizations (Larsson & Gill, 2021; Keswani et al,
170 2020). An explanation is provided by Jackson et al. (2020), who proved that allergic sensitization and allergen
171 natural exposure are inversely related to membrane-bound angiotensin-converting enzyme 2 (ACE-2)
172 expression, whereby it is known that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses the
173 ACE-2 receptor to gain cell entry, leading to COVID-19 (Wan et al., 2020). Additionally, it is hypothesized that
174 seasonal allergens, especially pollens and mold spores, compete with flu-like viruses for access to another
175 receptor, the Toll-like receptor 4 (TLR4) (Shah et al., 2021), in an attempt to explain the inverse seasonality of
176 seasonal allergens and flu-like illnesses, both for people with and without allergic diseases.

177 Another explanation is based on the higher eosinophil count in children with allergic diseases than COVID-19
178 patients (Licari et al., 2020), whereby eosinophils are known to clear viral load, and contribute to the recovery
179 from viral infections, supposedly including COVID-19 (Lindsley et al, 2020).

180 Furthermore, histamine and IgE serum levels are elevated in allergic rhinitis and other atopy patients which
181 downplay other anti-viral responses (plasmacytoid dendritic cells and interferon- α) but might thus prevent the
182 cytokine storm and hyper-inflammation that typically mark severe outcomes of respiratory diseases, including
183 COVID-19 (Carli et al., 2020) and influenza. Similarly, it is reported that pollen might suppress interferon- λ 1
184 and - λ 3 and pro-inflammatory chemokine responses in non-allergic subjects (Gilles et al, 2020).

185 Finally, it is well-established that pollens have anti-viral phytochemicals (Kappor et al, 2017), which is also the
186 case for mold spores (Linnakoski, 2018). Although the nature of the bioaerosol interaction with COVID-19
187 viruses is not well-investigated yet it can be hypothesized that pollens and spores compete with viral bioaerosol
188 in the environment.

189 *Logarithmic Infection Scale*

190 A logarithmic infection scale seems to be useful for ILI or COVID-19. It plots the nonlinear, exponential curves
191 on a linearized scale. This allows for standard linear regression analysis. Furthermore, the 1 to 10 rational scale
192 is intuitive as it relates to the counting system we are all familiar with, and is quite similar to the well-established
193 Richter scale for earthquakes. The addition of descriptive terms, similar to what we are used to in other nonlinear
194 scales, might be helpful in quickly grasping the severity of an epidemic or pandemic in intuitive, layman terms.
195 And it makes comparison between different epidemics or pandemics easier. Finally, it enlarges the critical early
196 stages of an epidemic, and it reduces the extreme peaks and resulting test bias because of test capacity overloads.

197

198 *Methodological concerns*

199 Test bias, especially for new viruses like COVID-19, are a major methodological challenge. The approach to use
200 more reliable metrics like the number of hospitalizations to generate an alternative incidence metric appears to
201 be a good correction for test bias. Another sound approach used seems to be excess mortality estimates. In this
202 study, we decided not to use these, as there are other known factors than seasonal viruses that cause it, such as
203 the heat wave during the Summer of 2020. Using excess mortality would just introduce another bias.

204

205 **5. Conclusion**

206 The COVID-19 pandemic in the Netherlands is till now as seasonal as flu-like illnesses given the highly
207 significant and strong correlations between both time series. But, also given that COVID-19 waves till now rise
208 between the temporal boundaries (week 15 \pm 5 weeks and week 33 \pm 2 weeks) of the typical flu-like season in
209 The Netherlands, and go down in the opposing periods. Further, the COVID-19 pandemic satisfies the
210 qualitative criteria of earlier respiratory pandemics since 1889: the first wave is short-lived at the tail-end of flu
211 season, the second wave is longer and more severe, peaks fall within the boundaries of flu-like season, and the
212 lows are during the boundaries of the opposing season.

213

214 **References**

215 Boore D.M., The Richter scale: its development and use for determining earthquake source parameters,
216 Tectonophysics, Volume 166, Issues 1–3, 1989, p1-14, [https://doi.org/10.1016/0040-1951\(89\)90200-X](https://doi.org/10.1016/0040-1951(89)90200-X).

- 217 Brandelius A., Andersson M. & Uller L. (2020). Topical dsRNA challenges may induce overexpression of
218 airway antiviral cytokines in symptomatic allergic disease. A pilot in vivo study in nasal airways. *Respiratory*
219 *Medicine*, vol 108(12) 1816-1819 <https://doi.org/10.1016/j.rmed.2014.10.010>
- 220 Carli, G., Cecchi, L., Stebbing, J., Parronchi, P., & Farsi, A. (2020). Is asthma protective against COVID-19?
221 *Allergy*, <https://doi.org/10.1111/all.14426>
- 222 Fox S.J., Miller J.C., & Meyers L.A. (2017). Seasonality in risk of pandemic influenza emergence. *PLoS*
223 *Comput Biol.* Oct; 13(10): e1005749. doi: 10.1371/journal.pcbi.1005749.
- 224 Gilles, S, Blume, C, Wimmer, M, et al. Pollen exposure weakens innate defense against respiratory viruses.
225 *Allergy*. 2019; 75: 576– 587. <https://doi.org/10.1111/all.14047>
- 226 Grech, V., Cuschieri, S., & Gauci, C. COVID-19: The possible seasonal shape of things to come. *Early Human*
227 *Development*, 2020, 105262, ISSN 0378-3782, <https://doi.org/10.1016/j.earlhumdev.2020.105262>.
- 228 Hoogeveen M.J. (2020). Pollen likely seasonal factor in inhibiting flu-like epidemics. A Dutch study into the
229 inverse relation between pollen counts, hay fever and flu-like incidence 2016–2019, *Science of The Total*
230 *Environment*, Vol. 727, 2020, <https://doi.org/10.1016/j.scitotenv.2020.138543>.
- 231 Hoogeveen M.J, Van Gorp, E.C.M. and Hoogeveen, E.K. Can pollen explain the seasonality of flu-like illnesses
232 in the Netherlands?, *Science of The Total Environment*, Volume 755, Part 2, 10 February 2021, 143182.
233 <https://doi.org/10.1016/j.scitotenv.2020.143182>.
- 234 Howarth, P.H. (2000). Allergic rhinitis: not purely a histamine-related disease. *European Journal of Allergy and*
235 *Clinical Immunology*, Vol 55(s64), 7-16.
- 236 Kapoor, R., Sharma, B. and Kanwar, S.S. Antiviral Phytochemicals: An Overview. *Biochem Physiol*, 2017, 6:2,
237 DOI: 10.4172/2168-9652.1000220.
- 238 Kerr, G.H., Badr, H.S., Gardner, L.M., Perez-Saez, J. & Zaitchik, B.F., Associations between meteorology and
239 COVID-19 in early studies: Inconsistencies, uncertainties, and recommendations, *One Health*, Volume 12, 2021,
240 <https://doi.org/10.1016/j.onehlt.2021.100225>.
- 241 Keswani, A., Dhana, K., Rosenthal, J.A., Moore, D. & Mahdavinia, M.. *Ann Allergy Asthma Immunol*. 2020
242 Oct; 125(4): 479–481. Published online 2020 Jul 18. doi: 10.1016/j.anai.2020.07.012

- 243 Kissler S.M., Tedijanto C., Goldstein E., Grad Y.H. & Lipsitch M. (2020). Projecting the transmission dynamics
244 of SARS-CoV-2 through the post-pandemic period. *Science* 10.1126/science.abb5793.
- 245 Klemens, C., Rasp, G., Jund, F., Hilgert, E., Devens, C., Pfrogner, E., Kramer, M.F. Mediators and cytokines in
246 allergic and viral-triggered rhinitis. *Allergy & Asthma Proceedings* . Jul/Aug 2007, Vol 28(4), 434-441.
- 247 Larsson, S.C. & Gill, D. Genetic predisposition to allergic diseases is inversely associated with risk of COVID-
248 19. *Allergy*, 2021. <https://doi.org/10.1111/all.14728>.
- 249 Licari, A., Votto, M., Brambilla, I., Castagnoli, R., Piccotti, E., Olcese, R., Tosca, M.A., Ciprandi, G. and
250 Marseglia, G.L. (2020), Allergy and asthma in children and adolescents during the COVID outbreak: What we
251 know and how we could prevent allergy and asthma flares. *Allergy*. doi:10.1111/all.14369.
- 252 Lindsley A.W., Schwartz J.T., Rothenberg M.E.. Eosinophil responses during COVID-19 infections and
253 coronavirus vaccination. *J Allergy Clin Immunol*. 2020; <https://doi.org/10.1016/j.jaci.2020.04.021>
- 254 Linnakoski, R., Reshamwala, D., Veteli, P., Cortina-Escribano, M., Vanhanen, H. & Marjomäki, V. Antiviral
255 agents from fungi: diversity, mechanisms and potential applications. *Front. Microbiol.* 9, 2325 (2018)
256 <https://doi.org/10.3389/fmicb.2018.02325>.
- 257 Moriyama M., Hugentobler W.J. & Iwasaki A.. Seasonality of Respiratory Viral Infections. *Annual Review of*
258 *Virology* 2020 7:1. <https://doi.org/10.1146/annurev-virology-012420-022445>.
- 259 Poole, L., Seasonal Influences On The Spread Of SARS-CoV-2 (COVID19), Causality, and Forecastabililty (3-
260 15-2020) (March 15, 2020). <http://dx.doi.org/10.2139/ssrn.3554746>
- 261 RIVM.nl (2021). *Epidemiologische situatie SARS-CoV-2 Nederland 02-02-2021*.
- 262 RIVM.nl/NICE (2021). *Estimated prevalence COVID-19 on the basis of a 95% confidence interval*.
263 https://data.rivm.nl/covid-19/COVID-19_prevalentie.json
- 264 Sajadi, M.M., Habibzadeh, P., Vintzileos, A., Shokouhi, S., Miralles-Wilhelm, F., & Amoroso, A. Temperature,
265 Humidity and Latitude Analysis to Predict Potential Spread and Seasonality for COVID-19 (March 5, 2020).
266 <http://dx.doi.org/10.2139/ssrn.3550308>.
- 267 Shah, R.B., Shah, R.D., Retzinger, D.G., Retzinger, A.C., Retzinger, D.A., & Retzinger, G.S. Confirmation of
268 an Inverse Relationship between Bioaerosol Count and Influenza-like Illnesses, Including COVID-19. On the
269 Contribution of Mold Spores. *MedRxiv pre-print* doi: <https://doi.org/10.1101/2021.02.07.21251322>.

270 Steffen, R., MD, Travel vaccine preventable diseases—updated logarithmic scale with monthly incidence rates,
 271 Journal of Travel Medicine, Volume 25, Issue 1, 2018, tay046, <https://doi.org/10.1093/jtm/tay046>.

272 Reuters (2021). Reuters COVID-19 tracker Europe [https://graphics.reuters.com/world-coronavirus-tracker-and-](https://graphics.reuters.com/world-coronavirus-tracker-and-maps/regions/europe/)
 273 [maps/regions/europe/](https://graphics.reuters.com/world-coronavirus-tracker-and-maps/regions/europe/).

274 Rosenwasser, L. J. (2011). Current Understanding of the Pathophysiology of Allergic Rhinitis. Immunology and
 275 Allergy Clinics, Vol 31(3), p 433 – 439.

276 Tamerius, J., Nelson, M. I., Zhou, S. Z., Viboud, C., Miller, M. A., & Alonso, W. J. (2011). Global influenza
 277 seasonality: reconciling patterns across temperate and tropical regions. Environmental health perspectives,
 278 119(4), 439–445. <https://doi.org/10.1289/ehp.1002383>.

279 Wan, Y. et al. (2020). J. Virol. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based
 280 on Decade-Long Structural Studies of SARS Coronavirus. [Epub ahead of print].
 281 <https://jvi.asm.org/content/94/7/e00127-20.long>

282

283 **Figures and Tables**

2*LOG₁₀(Incidence/100K)	Incidence (/100K citizens)	Incidence (% of population infected)	Description
0	1	0.001%	Isolated incidents
1	3	0.003%	Mild outbreak
2	10	0.01%	Moderate outbreak
3	30	0.03%	Severe outbreak
3.5	58	0.06%	Epidemic threshold (example)
4	100	0.1%	Mild Epidemic
5	300	0.3%	Moderate epidemic
6	1000	1%	Severe epidemic
7	3000	3%	Very severe epidemic
8	10000	10%	Public health catastrophe

9	30000	30%	Severe public health catastrophe
10	100000	100%	Total public health catastrophe


284 *Table 1: Logarithmic scale [1, 10] of ILI or CLI (or other) incidence because of the exponential nature of*
 285 *epidemics, with proposed qualitative descriptions for convenience.*

Variable	Mean	SD	2*Log ₁₀ transformed	
			Mean	SD
Average incidence ILI/100K 2016 till 2019	46	36	3.07	0.69
COVID-19 incidence/100K	126	141	3.34	1.43
COVID-19 incidence/100K estimate based on hospitalizations (average)	415	337	4.69	1.17
COVID-19 incidence/100K estimate based on hospitalizations (low 95% CI)	300	247	4.38	1.22
COVID-19 incidence/100K estimate based on hospitalizations (high 95% CI)	531	426	4.93	1.14

286 *Table 2: Overview of means (M) and standard deviations (SD) per variable in the dataset, including 2*Log₁₀*
 287 *transformed data.*

288

289



290

291 *Fig. 2. Scatter diagram showing the relation between COVID-19 incidence/100K citizens (Y-axis) and the*
 292 *seasonal, average ILI incidence/100K citizens (X-axis) in the Netherlands of the preceding 4 years.*


293

2*LOG₁₀(ILI/100K)	Estimate	95%CI	Intercept	R²	F-stat on DF	P<
2*LOG₁₀(COVID-19 incidence/100K)	1.81	1.34 to 2.28	1.95	0.59	61.45 (1, 43)	0.0001
2*LOG₁₀(COVID-19 incidence/100K) estimate based on hospitalizations	1.54	1.20 to 1.89	0.19	0.65	81.18 (1, 43)	0.0001

294

295 *Table 3: Highly significant outcomes of univariate regression analyses of the average ILI incidence/100K*
 296 *citizens on both time series for COVID-19 incidence/100K citizens, whereby each time series is 2*LOG₁₀*
 297 *transformed to compensate for non-linearity, and thus plotted on a 1 to 10 rational scale.*

298




299

300 *Fig. 1. Historical ILI incidence versus COVID-19 incidence per 100K citizens during the 2020/2021 season.*
301 *Peaks are all during flu season, and lows during the opposite season. The shaded periods are the typical period*
302 *in which seasonal switching occurs.*

303

304



305


306 *Fig. 2. Historical ILI incidence versus COVID-19 incidence per 100K citizens on the 1 to 10 logarithmic scale. It*
 307 *visualizes how similar the COVID-19 time series based on hospitalizations is with the historic ILI time series.*

308 *The shaded areas are the typical seasonal switching periods.*

309

310


311 **Linear Regression**



312

Best-fit values	
Slope	1.810 ± 0.2309
Y-intercept	-1.946 ± 0.6886
X-intercept	1.075
1/Slope	0.5524
95% Confidence Intervals	
Slope	1.344 to 2.276
Y-intercept	-3.335 to -0.5566
X-intercept	0.4106 to 1.477
Goodness of Fit	
R square	0.5883
Sy.x	0.9350
Is slope significantly non-zero?	
F	61.45
DFn,DFd	1,43
P Value	< 0.0001
Deviation from horizontal?	Significant
Data	
Number of XY pairs	45
Equation	$Y = 1.810 \cdot X - 1.946$

313



314

Best-fit values	
Slope	1.544 ± 0.1714
Y-intercept	0.1862 ± 0.5111
X-intercept	-0.1206
1/Slope	0.6475
95% Confidence Intervals	
Slope	1.198 to 1.890
Y-intercept	-0.8450 to 1.217
X-intercept	-1.011 to 0.4491
Goodness of Fit	
R square	0.6537
Sy.x	0.6939
Is slope significantly non-zero?	
F	81.18
DFn,DFd	1,43
P Value	< 0.0001
Deviation from horizontal?	Significant
Data	
Number of XY pairs	45
Equation	Y = 1.544*X + 0.1862

315